AbCellera Biologics Inc.

NASDAQ:ABCL

Biotechnology

Healthcare
$11.02 -0.28%

-$0.02 today

Market cap
$3.60B
Beta
1.20
P/E (TTM)
-11.4
EPS (TTM)
-$0.47
52W Low $2.75High $6.79

Volume 2.58M

Average 6.37M

ABCL Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

AbCellera Biologics Inc.NASDAQ: ABCL

Accounts Payables · Q3 FY2026 · quarter ended Sep 2026

Accounts payables dips below year-ago levels

Q3 FY2026 accounts payables of $3.31M fell 34.7% year over year, behind the +229.2% change in trailing-twelve-month accounts payables. Over 3 fiscal years it compounded at +48.0% a year.

Context

  • Accounts payables amounted to 4.6% of revenue in FY2025, down 32.3 pp from a year earlier.
  • Accounts payables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -34.7% toward the trailing-twelve-month pace of +229.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$3.31M+145.9% QoQ
Last fiscal yearDec 2025
$3.46M-67.5% YoY
LTMSep 2026
-$7.53M+229.2% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-34.7%——
1 year-67.5%——
3-year CAGR+48.0%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
3.46M USD
Year-over-year change
-67.5%
4-year CAGR
+25.4%

Accounts Payables vs competitors

How ABCL compares with its peers on the latest reported figures

  • ABCL's LTM Sep 2026 accounts payables of $7.53M is the 2nd largest of the 4 companies compared; the peer median is $2.17M.
  • Its year-over-year change of +229.2% is the highest of 4, against a peer median of -170.0%.
  • Accounts payables amounts to 11.1% of revenue for ABCL, versus a peer median of 30.5%.
ABCL Competitors Peer median
Accounts Payables for ABCL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DNAGinkgo Bioworks Holdings, Inc.LTM Mar 2026$43.13M -13619.7%-34.9%30.5%
ABCLAbCellera Biologics Inc.LTM Sep 2026$7.53M +229.2%+48.0%11.1%
ABSIAbsci CorporationLTM Mar 2026$2.17M -170.0%—118.3%
GENBGenerate Biomedicines, Inc.FY2025$2.13M -160.9%—6.7%
Peer median (excluding ABCL) $2.17M-170.0%-34.9%30.5%

Competitors are the stored peer set for ABCL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income153.46M158.52M(146.4M)(162.86M)(146.41M)
Depreciation & Amortization17.25M33.1M30.89M97M28.82M
Deferred Income Tax(2.02M)(2.11M)1.96M00
Stock-Based Compensation30.65M49.48M64.18M67.58M55.79M
Change in Working Capital41.67M29.83M13.23M(25.84M)(70.69M)
Accounts Receivables22.48M(22.72M)(45.93M)(75.12M)(55.62M)
Inventory0018.25M00
Accounts Payables1.4M1.07M(15.1M)10.64M3.46M
Other Working Capital17.79M51.47M56.01M38.64M(18.53M)
Other Non-Cash Items3.57M8.55M(7.74M)(84.44M)1.2M
Operating Cash Flow244.58M277.36M(43.88M)(108.56M)(131.3M)
Capital Expenditures(58.45M)(72.66M)(77.51M)(78.4M)(42.77M)
Acquisitions (Net)(11.46M)(25.68M)(13.69M)(19.63M)(7.14M)
Purchases of Investments(322.57M)(781.35M)(1.07B)(765.09M)(453.14M)
Sales of Investments27.61M510.63M910.94M948.81M506.07M
Other Investing Activities32.62M16.43M25.31M35.71M84.72M
Investing Cash Flow(332.25M)(352.63M)(221.11M)121.41M87.75M
Debt Repayment(951K)2.76M11.59M13.5M0
Common Stock Issued4.62M0000
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(7.55M)(4.38M)(1.23M)(729K)14.08M
Financing Cash Flow(3.89M)(1.63M)10.36M12.77M14.08M
Effect of Forex Changes(1.43M)(9.6M)589K(2.62M)1.1M
Net Change in Cash(92.97M)(86.49M)(254.04M)23.01M(28.37M)
Free Cash Flow186.13M204.7M(121.38M)(186.95M)(174.07M)

AbCellera Biologics Inc.

NASDAQ:ABCL

Intrinsic Alpha fair value

Locked

Current Price

$11.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.